Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study | Zendy

Hyun Cheol Chung | Zendy; Willeke Ros | Zendy; JeanPierre Delord | Zendy; Ruth Perets | Zendy; Antoîne Italiano | Zendy; Ronnie ShapiraFrommer | Zendy; Lyudmila Manzuk | Zendy; Sarina A. PihaPaul | Zendy; Lei Xu | Zendy; Susan Zeigenfuss | Zendy; Scott K. Pruitt | Zendy; Alexandra Léary | Zendy

Open Access

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Author(s) -

Hyun Cheol Chung,

Willeke Ros,

JeanPierre Delord,

Ruth Perets,

Antoîne Italiano,

Ronnie ShapiraFrommer,

Lyudmila Manzuk,

Sarina A. PihaPaul,

Lei Xu,

Susan Zeigenfuss,

Scott K. Pruitt,

Alexandra Léary

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.01265

Subject(s) - medicine , pembrolizumab , cervical cancer , oncology , phases of clinical research , expanded access , cancer , gynecology , clinical trial , immunotherapy

KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research